DIABETES MELLITUS: A REVIEW WITH EDGE OF SGLT2 INHIBITORS
The relative (Type 2 DM) or absolute (Type 1 DM) deficiency of insulin hormone could result into hyperglycemia, which is a characteristic feature of diabetes mellitus. Diabetes mellitus is a leading cause of morbidity and mortality because of its associated complications viz. Neuropathy, Nephropathy, Retinopathy, Cardiovascular disorders.
The feature which has to be noted down is the death of individuals before the age of 70 y, which is attributable to high blood glucose levels. According to WHO diabetes mellitus will be the seventh leading cause of deaths till 2030.
The induction of glycosuria as meant for glyÂcaemiac control in patients with DM is an extension of the physiological role of renal TmG to curb the menace of hyperglycemia. The first biologically derived SGLT2 inhibitor phlorizin, isolated in 1835 from the root bark of apple tree, was not developed as an antihyperglycaemic drug because of rapid degradation by lactase-phlorizin hydrolase and poor absorption from the gastrointestinal tract. Other glycoside moieties derived from phlorizin strucÂture have subsequently been developed recently.
2. American Diabetes Association: implications of the united kingdom prospective diabetes study. Diabetes Care 2004; 27(Suppl 1):28â€“32.
3. Zucchi P, Ferrari P, Spina ML. Diabetic foot: from diagnosis to therapy. G Ital Nefrol 2005,22(Suppl 31):S20-S22.
4. Mohan D, Raj D, Shanthirani CS, Datta M, Unwin NC, Kapur A. Awareness and knowledge of diabetes in Chennai-The Chennai urban, rural epidemiology study. J Assoc Physicians India 2005; 53:283â€“7.
5. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
6. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2011;34(Suppl 1)S62â€“S69.
7. Www.drugs.com/diabetes-treatment.html. [Last assessed on 21 Apr 18].
8. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005;21:31â€“8.
9. Ellsworth BA. Aglycone exploration of C arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2. Bioorg Med Chem Lett 2008;18:4770â€“3.
10. Meng W. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51:1145â€“9.
11. Nomura S. Discovery of canagliflozin, a novel C glucoside with thiophene ring, assodium-dependent glucose cotransporter 2 inhibitors for the treatment of type 2 diabetes mellitus. J Med Chem 2010;53:6355â€“60.
12. Obermeier M. In vitro characterization and pharmacokinetics of dapagliflozin (BMS 512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos 2010;38:405â€“14.
13. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2217â€“24.
14. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomized, double-blind, placebo-controlled trial. Lancet 2010;375:2223â€“33.
15. Wilding JP. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009;32:1656â€“62.
16. Kasichayanula S. Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects. Diabetes Obes Metab 2010;13:770â€“3.
17. Kasichayanula S. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitors, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab 2011;13:47â€“54.